Intellipharmaceutics International Inc. (IPCI)

[fabius]

Help needed for competitor's product analysis:

I was reading about Collegium (they were just included into the United Health list of drugs, causing an incredible price appreciation)and their recent submission of NDS to Helath Canada for their

" Xtampza® ER, an
Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain"

from their news release:
"ETERx® technology platform, providing adequate pain control while maintaining its extended-release profile even if subjected to common methods of manipulation, including chewing and crushing the product prior to administration. In addition, Xtampza ER supports the administration of the product by sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy or nasogastric feeding tube."

but

"Abuse of Xtampza ER by injection and by the nasal route of administration, as well as by the oral route is still possible."

"Xtampza ER is not indicated as an as-needed (prn) analgesic."

This was surprising...what about Rexista ?
"Accidental Ingestion
Accidental ingestion of even one dose of Xtampza ER, especially by children, can result in a fatal overdose of oxycodone."

Am I correct in saying that Rexista looks much superior ? Please elaborate.